Plain-English translation of NCT04069884 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether a genetic test called RecurIndex can help doctors make better decisions about radiation therapy for people with early-stage breast cancer who have cancer in 1–3 lymph nodes. The trial wants to see if using this genetic information can help some patients avoid unnecessary radiation to their lymph nodes while still getting excellent outcomes.
Currently, most patients with cancer in their lymph nodes receive radiation to the lymph node area as standard care. However, doctors think some of these patients may not actually need this extra radiation and could be spared its side effects if we could better predict who is truly at risk of cancer returning.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. One group will receive standard radiation to the whole breast (or chest wall if you had a mastectomy) plus radiation to the lymph nodes. The other group will receive radiation to the whole breast or chest wall only, without lymph node radiation. Your doctors will use your RecurIndex genetic test result and clinical information to guide these decisions. The study will follow your health outcomes over time to see if both groups do equally well.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China